|
CN1925855B
(zh)
|
2003-12-19 |
2010-06-16 |
普莱希科公司 |
开发Ret调节剂的化合物和方法
|
|
US7498342B2
(en)
*
|
2004-06-17 |
2009-03-03 |
Plexxikon, Inc. |
Compounds modulating c-kit activity
|
|
US7709645B2
(en)
*
|
2004-07-27 |
2010-05-04 |
Sgx Pharmaceuticals, Inc. |
Pyrrolo-pyridine kinase modulators
|
|
WO2006015123A1
(en)
|
2004-07-27 |
2006-02-09 |
Sgx Pharmaceuticals, Inc. |
Pyrrolo-pyridine kinase modulators
|
|
CA2573573A1
(en)
|
2004-07-27 |
2006-02-09 |
Sgx Pharmaceuticals, Inc. |
Fused ring heterocycle kinase modulators
|
|
US7626021B2
(en)
*
|
2004-07-27 |
2009-12-01 |
Sgx Pharmaceuticals, Inc. |
Fused ring heterocycle kinase modulators
|
|
WO2006058120A1
(en)
*
|
2004-11-22 |
2006-06-01 |
Vertex Pharmaceuticals Incorporated |
Bicyclic inhibitors or rho kinase
|
|
US7846941B2
(en)
*
|
2005-05-17 |
2010-12-07 |
Plexxikon, Inc. |
Compounds modulating c-kit and c-fms activity and uses therefor
|
|
UA95244C2
(ru)
*
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
WO2007059219A1
(en)
*
|
2005-11-15 |
2007-05-24 |
Vertex Pharmaceuticals Incorporated |
Azaindazoles useful as inhibitors of kinases
|
|
US20130096302A1
(en)
*
|
2005-11-22 |
2013-04-18 |
Hayley Binch |
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
|
|
DE102007010953A1
(de)
*
|
2006-03-03 |
2007-09-06 |
Chemetall Gmbh |
Magnesiumorganisches Synthesemittel
|
|
US20070286864A1
(en)
*
|
2006-06-09 |
2007-12-13 |
Buck Elizabeth A |
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
|
|
CL2007002617A1
(es)
*
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
|
BRPI0717320A2
(pt)
*
|
2006-10-23 |
2013-10-22 |
Sgx Pharmaceuticals Inc |
Triazóis bicíclicos como moduladores de proteína cinase
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
PE20121126A1
(es)
*
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
|
JP2010514695A
(ja)
|
2006-12-21 |
2010-05-06 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物および方法およびそのための適応症
|
|
MX2009010984A
(es)
*
|
2007-04-10 |
2010-01-15 |
Sgx Pharmaceuticals Inc |
Moduladores de heterociclo cinasa de anillo fusionado.
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
EP2162132A4
(en)
*
|
2007-05-21 |
2013-01-16 |
Sgx Pharmaceuticals Inc |
Heterocyclic kinase modulators
|
|
EP2157090A4
(en)
|
2007-06-21 |
2011-09-07 |
Taisho Pharmaceutical Co Ltd |
PYRAZINAMIDE COMPOUND
|
|
US20100210644A1
(en)
*
|
2007-06-25 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Chemical compounds
|
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
KR20090031122A
(ko)
*
|
2007-09-21 |
2009-03-25 |
주식회사 중외제약 |
인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
|
|
JP5368485B2
(ja)
*
|
2008-02-25 |
2013-12-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロロピラジンキナーゼインヒビター
|
|
CN101945877B
(zh)
*
|
2008-02-25 |
2013-07-03 |
霍夫曼-拉罗奇有限公司 |
吡咯并吡嗪激酶抑制剂
|
|
ES2372908T3
(es)
*
|
2008-02-25 |
2012-01-27 |
F. Hoffmann-La Roche Ag |
Inhibidores de la pirrolopirazina quinasa.
|
|
JPWO2009157423A1
(ja)
*
|
2008-06-24 |
2011-12-15 |
財団法人乙卯研究所 |
縮合環を有するオキサゾリジノン誘導体
|
|
CA2743134A1
(en)
|
2008-11-10 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8592448B2
(en)
*
|
2008-11-20 |
2013-11-26 |
OSI Pharmaceuticals, LLC |
Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
|
|
ES2921576T3
(es)
|
2008-12-19 |
2022-08-29 |
Vertex Pharma |
Compuestos útiles como inhibidores de la quinasa ATR
|
|
MY172424A
(en)
*
|
2009-04-03 |
2019-11-25 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
CN102595899A
(zh)
*
|
2009-08-10 |
2012-07-18 |
埃皮瑟瑞克斯有限公司 |
作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
|
|
CN105037355B
(zh)
|
2009-08-10 |
2017-06-06 |
萨穆梅德有限公司 |
Wnt信号传导途径的吲唑抑制剂及其治疗用途
|
|
IN2012DN01983A
(https=)
|
2009-08-24 |
2015-07-24 |
Ascepion Pharmaceuticals Inc |
|
|
CN106220623A
(zh)
|
2009-11-06 |
2016-12-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
|
LT3001903T
(lt)
|
2009-12-21 |
2018-01-10 |
Samumed, Llc |
1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
|
|
MX2012008642A
(es)
*
|
2010-01-27 |
2012-11-23 |
Vertex Pharma |
Inhibidores de cinasas de pirazolopiridinas.
|
|
JP5769733B2
(ja)
*
|
2010-01-27 |
2015-08-26 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
ピラゾロピリジンキナーゼ阻害剤
|
|
WO2011109593A1
(en)
*
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Substituted-5-aminopyrrolo/pyrazolopyridines
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
CA2798760A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2-aminopyridine derivatives useful as inhibitors of atr kinase
|
|
NZ603477A
(en)
|
2010-05-12 |
2014-09-26 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase
|
|
US9334244B2
(en)
|
2010-05-12 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2568984A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
MX2013000103A
(es)
*
|
2010-06-23 |
2013-06-13 |
Vertex Pharma |
Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
|
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
|
US9624213B2
(en)
|
2011-02-07 |
2017-04-18 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
|
US8791112B2
(en)
|
2011-03-30 |
2014-07-29 |
Arrien Pharmaceuticals Llc |
Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
|
|
MX2013011450A
(es)
|
2011-04-05 |
2014-02-03 |
Vertex Pharma |
Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
JP2014513724A
(ja)
|
2011-05-16 |
2014-06-05 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
融合二環キナーゼ阻害剤
|
|
US8822469B2
(en)
|
2011-06-22 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
|
|
EP2723747A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
IN2014CN02646A
(https=)
|
2011-09-14 |
2015-08-07 |
Samumed Llc |
|
|
WO2013049722A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8765751B2
(en)
|
2011-09-30 |
2014-07-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
CN106496173A
(zh)
|
2011-09-30 |
2017-03-15 |
沃泰克斯药物股份有限公司 |
用于制备可用作atr激酶抑制剂的化合物的方法
|
|
CN108685922A
(zh)
|
2011-09-30 |
2018-10-23 |
沃泰克斯药物股份有限公司 |
用atr抑制剂治疗胰腺癌和非小细胞肺癌
|
|
US8846917B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8846918B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2015502925A
(ja)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8841337B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013096496A2
(en)
|
2011-12-21 |
2013-06-27 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
CN108478577A
(zh)
|
2012-04-05 |
2018-09-04 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物及其组合疗法
|
|
NZ629282A
(en)
|
2012-05-04 |
2017-04-28 |
Samumed Llc |
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
EP2909202A1
(en)
|
2012-10-16 |
2015-08-26 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
MX2015004615A
(es)
*
|
2012-10-16 |
2015-07-17 |
Hoffmann La Roche |
Inhibidores de serina/treonina cinasa.
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
US9260426B2
(en)
*
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
EP2943198B1
(en)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
US9206188B2
(en)
*
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
KR20160055170A
(ko)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 아세트아미드 화합물 및 이의 사용 방법
|
|
PT3077397T
(pt)
|
2013-12-06 |
2020-01-22 |
Vertex Pharma |
Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
|
|
CN103980272B
(zh)
*
|
2014-04-18 |
2016-02-17 |
海门瑞一医药科技有限公司 |
一种合成5-氰基-1H-吡唑并[3,4-b]吡啶的方法
|
|
MX373102B
(es)
|
2014-06-05 |
2020-04-17 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
|
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016164641A1
(en)
*
|
2015-04-08 |
2016-10-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2017015152A1
(en)
|
2015-07-17 |
2017-01-26 |
Memorial Sloan-Kettering Cancer Center |
Combination therapy using pdk1 and pi3k inhibitors
|
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10226453B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
SG10201913990RA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
MX380092B
(es)
|
2015-11-06 |
2025-03-11 |
Samumed Llc |
Tratamiento de la osteoartritis.
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
MX390577B
(es)
|
2016-06-01 |
2025-03-20 |
Samumed Llc |
Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida.
|
|
JP2019535672A
(ja)
|
2016-10-21 |
2019-12-12 |
サミュメッド リミテッド ライアビリティ カンパニー |
インダゾール−３−カルボキサミドの使用方法およびｗｎｔ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用
|
|
MA46696A
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed Llc |
Formulations injectables à dose unique prêtes à l'emploi
|
|
US11331313B2
(en)
|
2017-05-22 |
2022-05-17 |
Whitehead Institute For Biomedical Research |
KCC2 expression enhancing compounds and uses thereof
|
|
JP2021514359A
(ja)
|
2018-02-15 |
2021-06-10 |
ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． |
キナーゼ阻害剤としての複素環式化合物
|
|
KR102108414B1
(ko)
*
|
2018-11-21 |
2020-05-11 |
중앙대학교 산학협력단 |
Aurka 매개 kdm6b 활성 조절을 통한 암세포 분화 조절 용도
|
|
TWI848141B
(zh)
*
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
US12459958B2
(en)
|
2019-07-17 |
2025-11-04 |
Beone Medicines I Gmbh |
Tricyclic compounds as HPK1 inhibitor and the use thereof
|
|
US20220281859A1
(en)
*
|
2019-08-14 |
2022-09-08 |
Nuvation Bio Inc. |
Heterocyclic compounds as kinase inhibitors
|
|
CN113429408A
(zh)
*
|
2021-07-07 |
2021-09-24 |
南方科技大学 |
含氮杂环化合物及其制备方法、药物组合物和应用
|
|
CN118834206A
(zh)
*
|
2023-04-24 |
2024-10-25 |
北京宇繁科技有限责任公司 |
一种map4k4抑制剂及其制备方法和应用
|